查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103684

膠質母細胞瘤多形性疾病治療市場：全球市場預測，2026-2032年

Glioblastoma Multiforme Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，多形性膠質母細胞瘤治療市場將成長至 64.1 億美元，複合年成長率為 8.35%。

主要市場統計數據
基準年 2025 36.5億美元
預計年份：2026年 39.7億美元
預測年份：2032年 64.1億美元
複合年成長率 (%) 8.35%

由於膠質母細胞瘤具有高度侵襲性的生物學特性、廣泛的腦浸潤、高復發率以及現有標準治療療效有限，其治療仍然是神經腫瘤學領域最緊迫和最複雜的挑戰之一。治療方案通常包括最大限度地安全切除腫瘤、放射線治療、替Temozolomide化療、針對特定患者的腫瘤電療、皮質類固醇和抗癲癇藥物治療、復健以及安寧療護。儘管神經外科在導航技術、分子診斷和多學科診療方面取得了進展，但由於腫瘤異質性、血腦障壁的限制、免疫抑制性腫瘤微環境以及抗藥性膠質瘤幹細胞樣細胞群的存在，造口細胞瘤的治療仍然面臨著巨大的臨床挑戰。

治療方案的發展越來越依賴生物標記，其中MGMT啟動子甲基化、IDH突變狀態、TERT啟動子突變、EGFR擴增、CDKN2A/B缺失以及更廣泛的基因組分析等指標具有重要的臨床意義。雖然這些標記有助於預後判斷、臨床檢測合格和治療分層，但它們也進一步強調了個人化治療方案而非統一治療方案的必要性。隨著人們對復發性膠質母細胞瘤治療的日益關注，臨床治療重點也在不斷調整，再次手術、再次放射治療、全身治療、器械介入治療以及臨床實驗免疫療法等治療方案的評估均基於患者的體能狀態、腫瘤位置、既往治療史和分子特徵。

圍繞膠質母細胞瘤治療、腦腫瘤治療、神經腫瘤臨床試驗、標靶治療、免疫療法、精準醫療以及腫瘤人工智慧等領域的搜尋興趣和臨床討論，反映出人們正朝著整合式醫療模式轉變。最具韌性的相關人員是那些致力於將臨床創新與實證醫學、監管合規、真實世界數據收集、患者就醫以及符合倫理規範的數位醫療基礎設施相結合的機構。

膠質母細胞瘤治療的變革性變化

多形性膠質母細胞瘤的治療格局正在經歷一場變革，從單一的標準治療轉向基於生物學見解的多方面、適應性治療策略。神經外科手術實踐正透過螢光引導切除、術中成像、清醒狀態下定位、功能性纖維束成像以及先進的導航系統不斷改進，從而在最大限度地安全切除腫瘤的同時最大限度地保留神經功能。放射治療計劃也隨著影像導引技術的改進、適應性計劃理念的引入以及復發風險評估的整合而變得更加精準。

人工智慧對膠質母細胞瘤治療的累積影響

人工智慧 (AI) 透過改善臨床醫生檢測、分類、後續觀察和治療惡性腦瘤的方式，對多形性膠質母細胞瘤的整體治療產生了累積影響。在神經影像學領域，AI 驅動的放射組學和深度學習模型可以輔助腫瘤分割​​、水腫評估、治療反應評估、區分進展和假性進展以及放射治療標靶區劃定。這些應用在膠質母細胞瘤治療中尤其重要，因為在放射線治療、放療、免疫療法或抗血管生成療法後，傳統影像檢查結果可能難以解讀。

膠質母細胞瘤治療的關鍵區域見解

在亞太地區，三級醫療網路的擴張、先進磁振造影技術的普及、神經外科手術能力的提升以及神經腫瘤學研究參與度的提高，正日益凸顯膠質母細胞瘤在多形性膠質母細胞瘤治療中的戰略重要性。儘管中國、印度、日本、韓國和澳洲等國正在加強分子診斷、放射治療和臨床實驗室基礎設施建設，但主要都市區與服務不足地區之間仍然存在醫療資源取得的差距。對經濟高效的診斷方法、可擴展的治療管道以及更廣泛地參與國際臨床實驗室服務的需求，正在推動該地區的轉型。

關鍵小組的見解影響膠質母細胞瘤的治療

隨著東協醫療體係不斷拓展癌症治療能力、改善磁振造影（MRI）的普及程度並加強神經外科和放射腫瘤科服務，東協正逐漸成為多形性膠質母細胞瘤治療的重要中心。然而，新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國的準備工作存在差異。儘管發達的都市區能夠提供多學科腦瘤治療，但農村地區往往面臨診斷延誤和分子檢測資源匱乏的問題。區域性臨床路徑和資訊發布系統的標準化有助於提高治療的連續性。

主要國家膠質母細胞瘤治療趨勢

美國擁有全球最完善的多形性膠質母細胞瘤治療體系之一，這得益於廣泛的神經腫瘤學研究、分子診斷和臨床檢測的機會、先進的神經外科和放射治療技術的創新，以及多學科腫瘤學會議的廣泛應用。在加拿大，以指南為基礎的癌症治療、學術性神經腫瘤學計畫和公平的跨省醫療服務模式備受重視，但地理距離可能會影響患者獲得專科治療的機會。在墨西哥，主要城市的腫瘤治療體係正在發展，為擴大分子檢測、放射治療和參與臨床檢測的機會提供了機會。

治療領導者使用的實用建議

產業領導者應優先考慮整合膠質母細胞瘤治療策略，將臨床證據、生物標記檢測、患者就醫途徑和真實世界治療結果結合。擴大分子診斷的普及至關重要，特別是MGMT啟動子甲基化、IDH狀態檢測，以及在臨床適用的情況下，更廣泛的二代定序。各機構應投資建構可互通的數據系統，將影像學、病理學、基因組學、治療史和治療結果等資訊連結起來，以支持精準醫療和研究證據的產生。

治療分析的調查方法

多形性膠質母細胞瘤治療分析的調查方法應建立在檢驗的二手研究、專家主導的初步研究結果以及臨床證據的系統性回顧之上。二手研究應包括同行評審的神經腫瘤學文獻、臨床實踐指南、監管出版刊物、癌症登記資訊、醫院診療方案參考資料、公共衛生資料庫、臨床實驗室登記資料以及科學會議論文集。應優先考慮那些報告透明的調查方法、具有臨床意義的終點指標以及可重複證據的資訊來源。

結論

多形性膠質母細胞瘤的治療正邁入一個更加先進的時代，其特點是精準診斷、精密的神經外科和放射治療技術、臨床實驗中的全身治療、人工智慧驅動的工作流程以及對以患者為中心的治療結果的日益重視。儘管該疾病仍然具有高度侵襲性和治療難度，但在分子分型、臨床實驗室設計、影像分析以及多學科診療協調等方面都取得了進展。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 膠質母細胞瘤多形性治療市場：依治療類型分類

  • 藥物治療
    • 化療
      • Carmustine
      • 合併化療
      • Temozolomide
    • 基因治療
      • 基因編輯
      • 溶瘤病毒療法
    • 免疫療法
      • 查核點抑制劑
      • 疫苗
    • 標靶治療
      • Bevacizumab
      • EGFR抑制劑
  • 放射線治療
    • 近距離放射治療
    • 體外放射治療
    • 放射外科
  • 支持性護理
    • 抗癲癇藥物
    • 皮質類固醇
  • 手術治療
    • 切片檢查程序
    • 開顱手術

第8章 膠質母細胞瘤多形性治療市場：依藥物類別分類

  • 烷化劑
    • Carmustine
    • Temozolomide
  • 查核點抑制劑
    • Nivolumab
    • Pembrolizumab
  • 單株抗體
  • 溶瘤病毒療法
  • 疫苗療法
    • 樹突細胞疫苗
    • 胜肽疫苗

第9章 膠質母細胞瘤多形性疾病治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 第三行

第10章 膠質母細胞瘤多形性治療市場：依最終使用者分類

  • 家庭醫療保健
  • 醫院
  • 研究機構
  • 專科診所

第11章 膠質母細胞瘤多形性治療市場：依分銷管道分類

  • 線上
  • 離線

第12章 多形性膠質母細胞瘤治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 膠質母細胞瘤多形性治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 膠質母細胞瘤多形性治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biohaven Ltd
  • Bluebird Bio Inc.
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics Inc.
  • Chimerix Inc.
  • CNS Pharmaceuticals Inc.
  • Daiichi Sankyo Company Limited
  • Eisai Co. Ltd
  • Eli Lilly and Company
  • Enterome SA
  • F. Hoffmann-La Roche Ltd
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Lantern Pharma Inc.
  • Medicenna Therapeutics Corp
  • Merck & Co. Inc.
  • Northwest BIoTherapeutics Inc.
  • Novartis AG
  • Novocure Ltd
  • Orbus Therapeutics Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • TuHURA Biosciences Inc.
  • Vigeo Therapeutics Inc.
Product Code: MRR-C002B1C996F6

The Glioblastoma Multiforme Treatment Market is projected to grow by USD 6.41 billion at a CAGR of 8.35% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.65 billion
Estimated Year [2026] USD 3.97 billion
Forecast Year [2032] USD 6.41 billion
CAGR (%) 8.35%

Glioblastoma multiforme treatment remains one of the most urgent and complex areas in neuro-oncology, driven by the disease's aggressive biology, diffuse brain infiltration, high recurrence rate, and limited durability of current standard-of-care options. Treatment pathways commonly combine maximal safe surgical resection, radiotherapy, temozolomide-based chemotherapy, tumor treating fields in selected patients, corticosteroid and anti-seizure management, rehabilitation, and palliative care support. Despite advances in neurosurgical navigation, molecular diagnostics, and multidisciplinary care, glioblastoma continues to present substantial clinical challenges due to tumor heterogeneity, blood-brain barrier constraints, immunosuppressive tumor microenvironments, and therapy-resistant glioma stem-like cell populations.

The treatment landscape is increasingly defined by biomarker-guided decision-making, with clinical relevance placed on MGMT promoter methylation, IDH mutation status, TERT promoter alterations, EGFR amplification, CDKN2A/B loss, and broader genomic profiling. These markers inform prognosis, trial eligibility, and treatment stratification, while reinforcing the need for individualized approaches rather than uniform treatment protocols. Growing attention to recurrent glioblastoma treatment is also reshaping clinical priorities, as repeat surgery, re-irradiation, systemic therapies, device-based interventions, and investigational immunotherapies are evaluated according to performance status, tumor location, prior treatment exposure, and molecular profile.

Search interest and clinical discourse around glioblastoma therapy, brain tumor treatment, neuro-oncology clinical trials, targeted therapy, immunotherapy, precision medicine, and artificial intelligence in oncology reflect a broader shift toward integrated care models. The most resilient stakeholders are those aligning clinical innovation with evidence generation, regulatory compliance, real-world data capture, patient access, and ethically governed digital health infrastructure.

Transformative Shifts in Glioblastoma Treatment

The glioblastoma multiforme treatment landscape is undergoing transformative shifts as care moves beyond a one-size-fits-all standard toward biologically informed, multimodal, and adaptive treatment strategies. Neurosurgical practice has improved through fluorescence-guided resection, intraoperative imaging, awake mapping, functional tractography, and advanced navigation systems that support maximal safe resection while preserving neurological function. Radiotherapy planning is also becoming more precise through image-guided techniques, adaptive planning concepts, and improved integration of recurrence-risk mapping.

Systemic therapy development is increasingly focused on overcoming historic barriers that have limited durable responses in glioblastoma. These include poor drug penetration across the blood-brain barrier, rapid tumor evolution, intratumoral heterogeneity, and immune evasion. As a result, investigational pipelines are emphasizing targeted therapies, vaccine-based approaches, checkpoint modulation strategies, oncolytic viruses, cell therapies, radiosensitizers, and novel drug delivery platforms such as convection-enhanced delivery, focused ultrasound-mediated blood-brain barrier disruption, and implantable local-release systems.

Another major shift is the expanding role of decentralized and biomarker-enriched clinical trials. Basket trials, adaptive trial designs, longitudinal molecular monitoring, and real-world evidence programs are helping researchers evaluate glioblastoma subgroups with greater precision. Patient-centered outcomes are also becoming more prominent, with increasing emphasis on neurocognitive preservation, functional independence, seizure control, quality of life, caregiver burden, and earlier integration of supportive care. These shifts are reframing glioblastoma treatment as a continuum of evidence-based clinical, molecular, digital, and supportive interventions.

Cumulative Impact of AI on Glioblastoma Treatment

Artificial intelligence is creating cumulative impact across glioblastoma multiforme treatment by improving the way clinicians detect, classify, monitor, and treat malignant brain tumors. In neuroimaging, AI-enabled radiomics and deep learning models can assist with tumor segmentation, edema assessment, treatment response evaluation, progression-versus-pseudoprogression differentiation, and radiotherapy target delineation. These applications are especially relevant in glioblastoma because conventional imaging can be difficult to interpret after chemoradiotherapy, immunotherapy, or anti-angiogenic treatment.

AI is also strengthening precision oncology workflows by integrating radiology, pathology, genomics, transcriptomics, methylation profiling, and clinical data into more comprehensive decision-support frameworks. Computational pathology can support grading, cellular morphology assessment, and microenvironment characterization, while machine learning models are being explored to predict MGMT methylation, IDH status, survival risk categories, and treatment response patterns. In clinical research, AI can accelerate trial matching, identify eligible patients based on molecular and imaging criteria, and improve protocol feasibility analysis.

The cumulative benefit of AI depends on validated algorithms, diverse training datasets, transparent performance reporting, interoperability with hospital systems, and strong governance around privacy, bias, explainability, and clinical accountability. AI is not replacing expert neuro-oncology judgment; rather, it is becoming an assistive layer that supports earlier insight, more consistent workflows, and better-informed treatment planning. Organizations that combine AI with clinically curated datasets, regulatory-grade validation, and multidisciplinary oversight are positioned to improve glioblastoma care delivery while maintaining patient safety and trust.

Key Regional Insights Across Glioblastoma Treatment

Asia-Pacific is gaining strategic relevance in glioblastoma multiforme treatment due to expanding tertiary hospital networks, rising access to advanced MRI, growing neurosurgical capacity, and increasing participation in neuro-oncology research. Countries such as China, India, Japan, South Korea, and Australia are strengthening capabilities in molecular diagnostics, radiotherapy, and clinical trial infrastructure, although access disparities remain between major urban centers and underserved regions. Demand for cost-effective diagnostics, scalable treatment pathways, and broader inclusion in global trials is shaping the region's evolution.

North America remains highly advanced in glioblastoma treatment due to established neuro-oncology centers, strong clinical trial ecosystems, high adoption of molecular profiling, and broad availability of advanced surgery, radiotherapy, systemic therapy, and supportive care services. The region is characterized by integrated academic care models, rapid uptake of digital health tools, and extensive research activity in immunotherapy, targeted therapy, tumor treating fields, and AI-enabled imaging analytics.

Latin America is progressing through the expansion of oncology infrastructure, improved radiation therapy access in leading urban hospitals, and growing awareness of brain tumor diagnosis and multidisciplinary care. However, uneven access to molecular testing, high out-of-pocket burden in some settings, and limited availability of specialized neuro-oncology programs continue to affect timely glioblastoma treatment. Regional collaboration, referral networks, and public-private clinical research participation are important enablers.

Europe demonstrates a mature and guideline-driven glioblastoma treatment environment, supported by cross-border research collaboration, centralized cancer registries in several countries, and strong adoption of molecular classification frameworks. European practice increasingly emphasizes standardized diagnostics, clinical trial access, quality-of-life assessment, and real-world evidence generation. Differences in reimbursement, diagnostic turnaround times, and access to emerging therapies remain important country-level considerations.

The Middle East is witnessing growth in glioblastoma treatment capabilities through investment in specialist oncology centers, advanced imaging, radiation oncology systems, and international clinical partnerships. GCC countries are particularly active in expanding high-complexity cancer care, while broader regional challenges include specialist workforce gaps, referral delays, and variable access to molecular diagnostics. Africa faces the greatest access constraints, with limited neuro-oncology capacity in many countries, shortages of radiotherapy infrastructure, delayed diagnosis, and affordability barriers. Nonetheless, regional centers of excellence, telemedicine, training partnerships, and pathology modernization are gradually improving the foundation for better glioblastoma care.

Key Group Insights Shaping Glioblastoma Treatment

ASEAN is emerging as an important corridor for glioblastoma multiforme treatment as health systems expand cancer care capacity, improve MRI access, and strengthen neurosurgical and radiation oncology services. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines show varying levels of readiness, with advanced urban centers offering multidisciplinary brain tumor care while rural populations often experience delayed diagnosis and limited access to molecular testing. Regional harmonization of clinical pathways and referral systems can improve continuity of care.

The GCC demonstrates strong potential in high-complexity glioblastoma treatment because of investment in modern oncology facilities, advanced radiotherapy platforms, genomic medicine programs, and international specialist partnerships. The region is increasingly focused on building local expertise, reducing outbound medical travel, and improving access to precision oncology. Standardized tumor boards, national cancer strategies, and digital health integration are supporting more coordinated neuro-oncology delivery.

The European Union benefits from robust regulatory frameworks, collaborative research networks, and widespread implementation of molecular tumor classification in glioblastoma diagnosis and treatment planning. EU-level emphasis on cancer research, data protection, health technology assessment, and cross-border scientific collaboration supports evidence-based adoption of innovative therapies. However, differences in national reimbursement processes and clinical trial availability can influence patient access.

BRICS countries represent a diverse treatment environment, combining large patient populations, expanding oncology infrastructure, and increasing interest in affordable innovation. China and India are scaling neurosurgical and diagnostic capacity, Brazil and South Africa are strengthening specialized cancer centers, and Russia maintains significant oncology and radiotherapy infrastructure. The group's common challenge is ensuring equitable access to molecular diagnostics, clinical trials, and advanced treatment technologies across urban and non-urban settings.

G7 countries generally lead in evidence generation, regulatory science, genomic diagnostics, and advanced neuro-oncology care. These nations are influential in shaping clinical guidelines, trial design, AI validation standards, and reimbursement models for glioblastoma treatment. NATO countries, while not a health policy bloc, include many nations with advanced biomedical research systems, military and civilian medical innovation networks, and strong imaging, rehabilitation, and digital health capabilities that can indirectly support brain tumor care innovation.

Key Country Insights in Glioblastoma Treatment

The United States has one of the most developed glioblastoma multiforme treatment ecosystems, supported by extensive neuro-oncology research, molecular diagnostics, clinical trial availability, advanced neurosurgery, radiotherapy innovation, and broad use of multidisciplinary tumor boards. Canada emphasizes guideline-based cancer care, academic neuro-oncology programs, and equitable provincial access models, although geographic distance can affect specialized care access. Mexico is advancing oncology capacity in major cities, with opportunities to expand molecular testing, radiotherapy access, and trial participation.

Brazil is Latin America's key glioblastoma treatment hub, supported by large tertiary hospitals, neurosurgical expertise, and growing oncology research activity, while persistent regional inequities affect timely diagnosis and treatment access. The United Kingdom maintains strong neuro-oncology clinical pathways, national guidance frameworks, and research networks, with increasing focus on molecular profiling and patient-centered outcomes. Germany is highly advanced in neurosurgery, radiotherapy, neuropathology, and translational research, making it a leading European center for glioblastoma care. France combines strong public hospital infrastructure, cancer research networks, and molecular diagnostics capabilities, while Italy and Spain continue to strengthen multidisciplinary neuro-oncology, radiotherapy modernization, and clinical trial access.

Russia has substantial oncology infrastructure and specialist centers, though access to newer diagnostics and therapies can vary by region. China is rapidly expanding glioblastoma treatment capabilities through major hospital networks, increasing MRI use, growing genomics capacity, and strong clinical research expansion. India faces a dual landscape of world-class tertiary neuro-oncology centers and broad access gaps, making affordability, early diagnosis, and referral efficiency critical priorities. Japan benefits from advanced imaging, neurosurgical precision, aging-population cancer care expertise, and structured research activity in malignant glioma. Australia has strong neuro-oncology care in metropolitan centers, robust clinical trial engagement, and increasing use of molecular tumor boards. South Korea demonstrates high adoption of advanced medical technologies, strong hospital infrastructure, and active research in precision oncology, imaging, and digital health applications for brain tumor care.

Actionable Recommendations for Treatment Leaders

Industry leaders should prioritize integrated glioblastoma treatment strategies that align clinical evidence, biomarker testing, patient access, and real-world outcomes. Expanding molecular diagnostic availability is essential, particularly for MGMT promoter methylation, IDH status, and broader next-generation sequencing where clinically appropriate. Organizations should invest in interoperable data systems that connect imaging, pathology, genomics, treatment history, and outcomes to support precision medicine and research-grade evidence generation.

Stakeholders should also strengthen partnerships with academic hospitals, cancer centers, patient advocacy groups, regulators, and payers to improve clinical trial enrollment, accelerate patient identification, and support ethically governed data sharing. For therapy developers, the focus should remain on blood-brain barrier penetration, rational combination regimens, validated biomarkers, recurrence-focused strategies, and endpoints that capture survival, neurocognition, function, and quality of life. For healthcare providers, standardized tumor boards, early palliative care integration, caregiver support, and rehabilitation services can improve continuity and patient-centered outcomes.

AI adoption should be pursued through validated, clinically supervised implementation rather than isolated experimentation. Leaders should assess algorithm performance across diverse populations, establish governance for bias monitoring, and ensure compliance with privacy and medical device regulations. In emerging and underserved regions, priorities should include workforce training, radiotherapy access, tele-neuro-oncology, pathology digitization, and referral network optimization. The most effective strategies will combine scientific innovation with operational execution and equitable care delivery.

Research Methodology for Treatment Analysis

The research methodology for glioblastoma multiforme treatment analysis should be grounded in validated secondary research, expert-led primary insights, and structured clinical evidence review. Secondary research includes peer-reviewed neuro-oncology literature, clinical practice guidelines, regulatory publications, cancer registry information, hospital protocol references, public health databases, clinical trial registries, and scientific conference proceedings. Priority should be given to sources that report transparent methodology, clinically relevant endpoints, and reproducible evidence.

Primary research may include structured interviews with neuro-oncologists, neurosurgeons, radiation oncologists, neuropathologists, radiologists, oncology nurses, clinical trial investigators, hospital administrators, diagnostic specialists, and patient support stakeholders. These interviews help contextualize treatment adoption, access barriers, diagnostic workflows, recurrence management, referral patterns, and real-world implementation challenges. Data triangulation is essential to reconcile clinical guidelines, published studies, regulatory status, and on-the-ground practice variation.

The analytical framework should classify glioblastoma treatment by therapy modality, disease setting, molecular biomarker relevance, care setting, patient pathway stage, and regional access conditions. Quality controls should include source validation, cross-referencing, exclusion of unsupported claims, and continuous review of evolving WHO tumor classification, clinical trial findings, and regulatory updates. The methodology should avoid unsupported market sizing or forecasting and instead focus on evidence-backed clinical, technological, regulatory, and access-related insights.

Conclusion

Glioblastoma multiforme treatment is entering a more sophisticated era shaped by precision diagnostics, advanced neurosurgical and radiotherapy techniques, investigational systemic therapies, AI-assisted workflows, and stronger emphasis on patient-centered outcomes. While the disease remains highly aggressive and difficult to treat, progress is visible in molecular classification, clinical trial design, imaging analytics, and multidisciplinary care coordination.

Regional and country-level differences continue to influence access to diagnosis, surgery, radiotherapy, molecular testing, and clinical trials. Advanced health systems are pushing innovation through biomarker-driven research and digital integration, while emerging regions are focusing on infrastructure, workforce development, affordability, and referral efficiency. Across all settings, the strongest opportunities lie in improving early diagnosis, expanding validated biomarker testing, optimizing recurrent glioblastoma care, and ensuring that innovation translates into accessible and evidence-based treatment.

Industry leaders that combine scientific rigor, ethical AI implementation, collaborative trial models, and equitable access strategies will be best positioned to advance glioblastoma care. The path forward requires coordinated action across clinicians, researchers, policymakers, technology developers, and patient communities to improve outcomes in one of oncology's most challenging diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Glioblastoma Multiforme Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Drug Therapy
    • 7.2.1. Chemotherapy
      • 7.2.1.1. Carmustine
      • 7.2.1.2. Combination Chemotherapy
      • 7.2.1.3. Temozolomide
    • 7.2.2. Gene Therapy
      • 7.2.2.1. Gene Editing
      • 7.2.2.2. Oncolytic Virus Therapy
    • 7.2.3. Immunotherapy
      • 7.2.3.1. Checkpoint Inhibitors
      • 7.2.3.2. Vaccines
    • 7.2.4. Targeted Therapy
      • 7.2.4.1. Bevacizumab
      • 7.2.4.2. EGFR Inhibitors
  • 7.3. Radiotherapy
    • 7.3.1. Brachytherapy
    • 7.3.2. External Beam Radiotherapy
    • 7.3.3. Radiosurgery
  • 7.4. Supportive Care
    • 7.4.1. Antiepileptic Drugs
    • 7.4.2. Corticosteroids
  • 7.5. Surgical
    • 7.5.1. Biopsy Procedures
    • 7.5.2. Craniotomy

8. Glioblastoma Multiforme Treatment Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Alkylating Agents
    • 8.2.1. Carmustine
    • 8.2.2. Temozolomide
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. Nivolumab
    • 8.3.2. Pembrolizumab
  • 8.4. Monoclonal Antibodies
  • 8.5. Oncolytic Virus Therapies
  • 8.6. Vaccine Therapies
    • 8.6.1. Dendritic Cell Vaccines
    • 8.6.2. Peptide Vaccines

9. Glioblastoma Multiforme Treatment Market, by Line Of Therapy

  • 9.1. Introduction
  • 9.2. First Line
  • 9.3. Second Line
  • 9.4. Third Line

10. Glioblastoma Multiforme Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Research Institutes
  • 10.5. Specialty Clinics

11. Glioblastoma Multiforme Treatment Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Online
  • 11.3. Offline

12. Glioblastoma Multiforme Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Glioblastoma Multiforme Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Glioblastoma Multiforme Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Amgen Inc.
  • 16.3. Amneal Pharmaceuticals Inc.
  • 16.4. AstraZeneca PLC
  • 16.5. Bayer AG
  • 16.6. Biohaven Ltd
  • 16.7. Bluebird Bio Inc.
  • 16.8. Bristol-Myers Squibb Company
  • 16.9. Celldex Therapeutics Inc.
  • 16.10. Chimerix Inc.
  • 16.11. CNS Pharmaceuticals Inc.
  • 16.12. Daiichi Sankyo Company Limited
  • 16.13. Eisai Co. Ltd
  • 16.14. Eli Lilly and Company
  • 16.15. Enterome SA
  • 16.16. F. Hoffmann-La Roche Ltd
  • 16.17. Karyopharm Therapeutics Inc.
  • 16.18. Kazia Therapeutics Limited
  • 16.19. Lantern Pharma Inc.
  • 16.20. Medicenna Therapeutics Corp
  • 16.21. Merck & Co. Inc.
  • 16.22. Northwest Biotherapeutics Inc.
  • 16.23. Novartis AG
  • 16.24. Novocure Ltd
  • 16.25. Orbus Therapeutics Inc.
  • 16.26. Pfizer Inc.
  • 16.27. Sun Pharmaceutical Industries Ltd
  • 16.28. Teva Pharmaceutical Industries Ltd
  • 16.29. TuHURA Biosciences Inc.
  • 16.30. Vigeo Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARMUSTINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARMUSTINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARMUSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMBINATION CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMBINATION CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMBINATION CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TEMOZOLOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TEMOZOLOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TEMOZOLOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BEVACIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BEVACIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BEVACIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EGFR INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EGFR INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EGFR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RADIOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EXTERNAL BEAM RADIOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EXTERNAL BEAM RADIOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EXTERNAL BEAM RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOSURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RADIOSURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIEPILEPTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIEPILEPTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIEPILEPTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SURGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SURGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SURGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPSY PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPSY PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPSY PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRANIOTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CRANIOTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRANIOTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARMUSTINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARMUSTINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARMUSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TEMOZOLOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TEMOZOLOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TEMOZOLOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NIVOLUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NIVOLUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NIVOLUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VACCINE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VACCINE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VACCINE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEPTIDE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PEPTIDE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEPTIDE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL THIRD LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL THIRD LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL THIRD LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 270. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 271. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 272. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 273. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 275. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 312. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 313. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 315. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 319. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 320. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2032 (USD MILLION)
  • TABLE 321. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 322. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 323. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2032 (USD MILLION)
  • TABLE 324. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 325. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 326. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 327. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 329. NATO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 330. NATO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. NATO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 332. NATO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 333. NATO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 334. NATO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 335. NATO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLI